Cedar Wealth Management’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Cedar Wealth Management’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-300	Closed	-$14K	–	382
2022 Q1	$14K	Hold	300	–	–	0.01%	278
2021 Q4	$14K	Hold	300	–	–	0.01%	274
2021 Q3	$14K	Hold	300	–	–	0.01%	222
2021 Q2	$16K	Hold	300	–	–	0.01%	220
2021 Q1	$15K	Hold	300	–	–	0.01%	199
2020 Q4	$16K	Hold	300	–	–	0.01%	185
2020 Q3	$13K	Hold	300	–	–	0.01%	183
2020 Q2	$13K	Hold	300	–	–	0.01%	179
2020 Q1	$11K	Buy	+300	New	+$12.8K	0.01%	185

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

CCMG

Clark Capital Management Group Philadelphia, Pennsylvania $18.3B AUM 36.97% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cedar Wealth Management's XPH Position: Q2 2022 in Review

Cedar Wealth Management sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2022, closing a stake of 300 shares — an estimated $14K sold.

Cedar Wealth Management first reported a position in XPH in Q1 2020 and held it in 9 quarters. The position peaked at $16K in Q2 2021. 71 funds tracked by Wall St. Rank hold XPH as of Q2 2022.

Cedar Wealth Management reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2022 after selling out during the quarter.
Cedar Wealth Management sold 300 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2022, an estimated $14K.
Cedar Wealth Management first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2020 and held it in 9 quarters.
Cedar Wealth Management's State Street SPDR S&P Pharmaceuticals ETF position peaked at $16K in Q2 2021.
71 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2022.

Based on Cedar Wealth Management's 13F filing for Q2 2022, filed 11 Aug 2022.